JNJ-632

• CAT Number: I020019
• CAS Number: 1572510-42-9
• Molecular Formula: C₁₈H₁₉FN₂O₄S
• Molecular Weight: 378.42
• Purity: ≥95%
• IUPAC Name: N-(4-fluoro-3-methylphenyl)-3-[[(3S)-oxolan-3-yl]sulfamoyl]benzamide
• InChI: InChI=1S/C18H19FN2O4S/c1-12-9-14(5-6-17(12)19)20-18(22)13-3-2-4-16(10-13)26(23,24)21-15-7-8-25-11-15/h2-6,9-10,15,21H,7-8,11H2,1H3,(H,20,22)/t15-/m0/s1
• InChIKey: JIZGLOVJKCSHTH-HNNXBMFYSA-N
• SMILES: CC1=C(C=CC(=C1)NC(=O)C2=CC(=CC=C2)S(=O)(=O)N[C@H]3CCOC3)F

JNJ-632（Cat No.:I020019）is a capsid assembly modulator (CAM) developed by Johnson & Johnson for the treatment of hepatitis B virus (HBV) infections. It inhibits HBV DNA replication in HepG2.2.15 and HepG2.117 cell lines, with EC₅₀ values of 0.12 and 0.43 μM, respectively. In vivo studies in C57BL/6 mice have shown that JNJ-632 has moderate plasma clearance and volume of distribution, with oral bioavailability ranging from 40% to 66% depending on the dose. These properties make JNJ-632 a promising candidate for further development in HBV therapy.

Reference

[1]. Vandyck K, et al. Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV). J Med Chem. 2018 Jul 26;61(14):6247-6260.